Navigation Links
3-V Biosciences Appoints Merdad V. Parsey, MD, PhD, as Chief Executive Officer
Date:9/30/2010

MENLO PARK, Calif., Sept. 30 /PRNewswire/ -- 3-V Biosciences, Inc. announced today the appointment of Merdad V. Parsey, MD, PhD as Chief Executive Officer.  

(Logo:  http://photos.prnewswire.com/prnh/20100513/LA04336LOGO)

(Logo:  http://www.newscom.com/cgi-bin/prnh/20100513/LA04336LOGO)

"We are very pleased to have Merdad as the new CEO of 3-V," said David M. Mott, 3-V's Executive Chairman, who is returning to his role as Chairman of the Board.  "Merdad's extensive drug development experiences in different therapeutic areas, including infectious disease, coupled with his experience in respiratory medicine, make him an excellent choice to lead the team."

Prior to joining 3-V Biosciences, Dr. Parsey held positions of increasing responsibility at Genentech, Inc., a member of the Roche Group, most recently as Senior Group Medical Director in Genentech Research and Early Development, overseeing early clinical development in multiple therapeutic areas.  Prior to his tenure with Genentech, Dr. Parsey worked at Sepracor, Regeneron and Merck, Inc. He has worked on multiple development and post-marketing programs from initial human trials to NDA/BLA submissions in Respiratory, Inflammation, Virology, Neurology, Ophthalmology and Gastrointestinal diseases.  In addition to his work in the biotechnology and pharmaceutical industries, Dr. Parsey was the Director of Critical Care Medicine at the NYU School of Medicine.  He completed his MD and PhD at the University of Maryland, his residency in Internal Medicine at Stanford University and his fellowship in Pulmonary and Critical Care Medicine at the University of Colorado.

"3-V has the opportunity, via the modulation of host-factor targets, to fundamentally change anti-viral treatment, and the company's founders, employees, and investors have created an environment to achieve this goal," said Dr. Parsey.  "I am excited to join the 3-V team and help turn this exciting science into therapies that have the potential to improve the lives of patients."

About 3-V Biosciences3-V Biosciences, Inc. is a privately-held biopharmaceutical company dedicated to discovering, developing and ultimately commercializing novel antiviral therapeutics that target host cell factors required for viral infection, thereby avoiding many of the shortcomings of traditional pathogen-directed approaches.  The company is located in Menlo Park, California and is financed by The Column Group, Kleiner Perkins Caufield Byers, and New Enterprise Associates.

For additional information on 3-V Biosciences, please visit www.3vbio.com.Contact informationStephen R. BradyVice President, Corporate Development, Strategy & Operations650-561-8600
'/>"/>

SOURCE 3-V Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Martek Biosciences Announces Agreement to Sell Majority of Winchester, Ky. Manufacturing Site
2. Signum Biosciences Awarded Two Additional NIH Grants for Development of Topical Therapeutics
3. Ardea Biosciences to Present at Four Upcoming Investor Conferences
4. Regado Biosciences to Present at the Stifel Nicolaus Healthcare Conference 2010 on September 16, 2010 in Boston, Massachusetts
5. HUYA Biosciences Establishes Strategic Partnership with Sun Yat-sen Universitys School of Pharmaceutical Sciences
6. InQ Biosciences Appoints John Ryder as Senior Vice President, Sales & Marketing
7. Neurocrine Biosciences Announces Conference Call and Webcast to Report Second Quarter 2010 Financial Results
8. Award Winning Mayo Clinic Scientist Joins Cardio3 BioSciences
9. SeqWrights Partnership with EraGen Biosciences Contributes to FDA Market Clearance Success
10. Signum Biosciences, Inc. Announces Commercial Launch of Arazine™
11. Sangamo BioSciences Announces Nature Biotechnology Study Demonstrating the Use of Zinc Finger Nucleases to Generate HIV Resistant Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/10/2017)... BURNIE, Md. , May 10, 2017 ... retention solutions for the clinical research industry, is proud ... www.CSSiEnroll.com . The new website features both enriched ... overall user experience and enhances the company,s already well-established ... the industry. "After many months of ...
(Date:5/9/2017)... , May 9, 2017  Semler Scientific, Inc. ... technology solutions to improve the clinical effectiveness and ... for the first quarter ended March 31, 2017. ... enable our customers to identify when preventive care ... before events like heart attacks or strokes occur," ...
(Date:5/6/2017)... 5, 2017  May is Stroke Awareness Month and ... most important methods to prevent a stroke: monitor and ... Disease Control and Prevention, undetected and uncontrolled hypertension is ... the global leader in personal heart health technology, recently ... heart attack and stroke and is advancing a national ...
Breaking Medicine Technology:
(Date:5/26/2017)... ... 26, 2017 , ... Rob Lowe acts as host and helps educate and ... on hiking in American. Viewers can reconnect with America as it explores some of ... Many consumers have looked for an inventive new place for a family vacation, and ...
(Date:5/26/2017)... ... 2017 , ... “When the Stars Lead Home”: a poignant story of loss, ... Laura Weigel Douglas, an avid reader who lives in the Pacific Northwest with her ... Green Hills Adventure Camp. She couldn’t be more grateful. , Twelve-year old Tizzy could ...
(Date:5/26/2017)... ... May 26, 2017 , ... Centennial-based BluSky Restoration Contractors announced ... 14th Annual Clays for Kids fundraiser, to be held Friday, Sept. 22, at ... As part of BluSky’s partnership with The Adoption Exchange, BluSky will also share ...
(Date:5/26/2017)... ... , ... “Cactus Jack: Against All Odds”: the story of Coach Cactus Jack ... All Odds” is the creation of published author, Walter Hubbard, a retired wildlife and ... third child Jane. Walter. Walter and Jane have three adult children and a ...
(Date:5/24/2017)... ... May 24, 2017 , ... Last month, representatives from ... employees, and town officials to celebrate the grand opening of the 87,000 square ... as part of its ongoing relationship with RWJBarnabas Health, New Jersey’s largest health ...
Breaking Medicine News(10 mins):